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BACKGROUND: Guidelines acknowledge the emerging role of high-
sensitivity cardiac troponin (hs-cTnl) for risk stratification and the early 
rule-out of myocardial infarction, but multiple thresholds have been 
described. We evaluate the safety and effectiveness of risk stratification 
thresholds in patients with suspected acute coronary syndrome.
METHODS: Consecutive patients with suspected acute coronary 
syndrome (n=48 282) were enrolled in a multicenter trial across 10 
hospitals in Scotland. In a prespecified secondary and observational 
analysis, we compared the performance of the limit of detection (<2 
ng/L) and an optimized risk stratification threshold (<5 ng/L) using the 
Abbott high-sensitivity troponin I assay. Patients with myocardial injury at 
presentation, with ≤2 hours of symptoms or with ST-segment elevation 
myocardial infarction were excluded. The negative predictive value was 
determined in all patients and in subgroups for a primary outcome of 
myocardial infarction or cardiac death within 30 days. The secondary 
outcome was myocardial infarction or cardiac death at 12 months, with 
risk modeled using logistic regression adjusted for age and sex.
RESULTS: In total, 32 837 consecutive patients (61±17 years, 47% 
female) were included, of whom 23 260 (71%) and 12,716 (39%) had 
hs-cTnl concentrations of <5 ng/L and <2 ng/L at presentation. The 
negative predictive value for the primary outcome was 99.8% (95% CI, 
99.7%–99.8%) and 99.9% (95% CI, 99.8%–99.9%) in those with hs-cTnl 
concentrations of <5 ng/L and <2 ng/L, respectively. At both thresholds, the 
negative predictive value was consistent in men and women and across all 
age groups, although the proportion of patients identified as low risk fell 
with increasing age. Compared with patients with hs-cTnl concentrations of 
≥5 ng/L but <99th centile, the risk of myocardial infarction or cardiac death 
at 12 months was 77% lower in those <5 ng/L (5.3% vs 0.7%; adjusted 
odds ratio, 0.23 [95% CI, 0.19–0.28]) and 80% lower in those <2 ng/L 
(5.3% vs 0.3%; adjusted odds ratio, 0.20 [95% CI, 0.14–0.29]).
CONCLUSIONS: Use of risk stratification thresholds for hs-cTnl identify 
patients with suspected acute coronary syndrome and at least 2 hours of 
symptoms as low risk at presentation irrespective of age and sex.
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The way in which cardiac troponin testing is used in clinical practice is evolving rapidly in parallel with major improvements in assay precision and 
sensitivity.1,2 High-sensitivity cardiac troponin assays are 
essential for the diagnosis of acute myocardial infarc-
tion but are increasingly also used in the assessment of 
cardiovascular risk to identify patients in the emergency 
department who are low risk and could be directly dis-
charged.3–9 Given that fewer than 10% of patients with 
suspected acute coronary syndrome have myocardial 
infarction,10 this application of high-sensitivity cardiac 
troponin testing has major potential to reduce unneces-
sary hospital admissions with benefits for patients and 
healthcare providers.
Although the universal definition of myocardial in-
farction recommends the use of sex-specific 99th cen-
tile or upper reference limits from a normal reference 
population as the diagnostic threshold for myocar-
dial infarction,3 there is less consensus on the optimal 
troponin threshold for the evaluation of cardiovascu-
lar risk.4,5 The ideal risk stratification threshold would 
permit the greatest number of patients without myo-
cardial infarction to be classified as low risk without 
compromising safety. The limit of detection has been 
proposed,11–13 but assay performance at this level is 
variable,  potentially reducing the consistency and ef-
fectiveness of this approach.14–17 We previously defined 
the optimal risk stratification threshold as the highest 
troponin concentration that gave a negative predictive 
value for myocardial infarction or cardiac death at 30 
days of at least 99.5%6 to maximize the number of 
patients identified as low risk while maintaining safety. 
This was achieved using a high-sensitivity cardiac tro-
ponin I assay at a concentration <5 ng/L, which identi-
fied two-thirds of patients as low risk at presentation 
and misclassified fewer than 1 in 200 patients. The only 
subgroup that did not meet this target for safety were 
those who presented within 2 hours of symptoms on-
set, and guidelines now clearly state that serial testing 
is required in these early presenters.3,7
The use of risk stratification thresholds in diagnostic 
pathways has been evaluated in retrospective analyses 
of cohort studies8,9 but have not been prospectively 
validated.4,18 Many approaches have been proposed, 
often in small cohorts of selected patients attending 
a single center, with a limited number of patients in 
high-risk subgroups. As such, there remains uncertainty 
as to the performance of these thresholds in practice, 
where patients are often older and more likely to have 
comorbidities. Our aim was to compare the diagnostic 
performance of an optimized risk stratification thresh-
old with the limit of detection, in the patient popula-
tion in whom risk stratification thresholds have been 
advocated by international guidelines.3 In a prespecified 
secondary and observational analysis of a multicenter 
trial of consecutive patients with suspected acute coro-
nary syndrome, we evaluate diagnostic performance in 
patients presenting with at least 2 hours of symptoms 
by age and in subgroups to provide reliable estimates 
for clinical practice. In a substudy of the trial popula-
tion, we explore the generalizability of this approach 
by evaluating performance of these risk stratification 
thresholds across different high-sensitivity assays.
METHODS
Transparency and Openness Promotion
The trial makes use of multiple routine electronic health care 
data sources that are linked, deidentified, and held in our 
national safe haven, which is accessible by approved individu-
als who have undertaken the necessary governance training. 
Summary data and the analysis code can be made available 
upon request from the corresponding author.
Study Population
High-STEACS (High-Sensitivity Troponin in the Evaluation of 
Patients With Suspected Acute Coronary Syndrome) was a 
stepped-wedge cluster randomized controlled trial that evalu-
ated the implementation of a high-sensitivity cardiac tropo-
nin I assay in consecutive patients presenting with suspected 
acute coronary syndrome across 10 secondary and tertiary 
Clinical Perspective
What Is New?
• In 32 837 consecutive patients with suspected 
acute coronary syndrome and at least 2 hours of 
symptoms, we evaluated the performance of 2 risk 
stratification thresholds for a high-sensitivity car-
diac troponin I assay.
• An optimized risk stratification threshold of <5 ng/L 
identified twice as many patients at presentation as 
low risk compared with the limit of detection (<2 
ng/L), with an equivalent negative predictive value 
for myocardial infarction or cardiac death at 30 days.
• Compared with the diagnostic threshold, patients 
with cardiac troponin I concentrations <2 ng/L or 
<5 ng/L were 80% and 77% lower risk of subse-
quent cardiac events at 12 months, respectively.
What Are the Clinical Implications?
• The use of separate risk stratification and diagnos-
tic thresholds for high-sensitivity cardiac troponin 
will improve the safety of our assessment of car-
diovascular risk in patients with suspected acute 
coronary syndrome.
• Incorporating a risk stratification threshold into the 
early evaluation of these patients will enable the 
majority of patients to avoid unnecessary hospi-
tal admission with major benefits for patients and 
healthcare providers.
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hospitals in Scotland (URL: https://www.clinicaltrials.gov. 
Unique identifier: NCT01852123). The study design has been 
described in detail previously19 and was conducted with the 
approval of the Scotland Research Ethics Committee in accor-
dance with the Declaration of Helsinki. Individual patient con-
sent was not sought. This approach ensured that consecutive 
patients presenting with suspected acute coronary syndrome 
were included without selection bias. All patients present-
ing to emergency departments between June 10, 2013, and 
March 3, 2016, were screened by the attending clinician and 
prospectively included in the trial if cardiac troponin was 
requested for suspected acute coronary syndrome.
For this prespecified secondary and observational analysis, 
we evaluate the performance of high-sensitivity cardiac tro-
ponin I in patients without evidence of myocardial injury at 
presentation (cardiac troponin concentrations below the sex-
specific 99th centile), excluding those patients who presented 
early (≤2 hours from symptom onset to the initial blood draw), 
or those with a ST-segment elevation myocardial infarction.
Substudy Population
To evaluate the generalizability of risk stratification thresh-
olds we used stored samples from a substudy of the trial to 
compare the performance of different high-sensitivity cardiac 
troponin I assays (Abbott ARCHITECTSTAT and Siemens Atellica, 
Siemens Healthineers) and high-sensitivity cardiac troponin 
T (Roche Elycsys, Roche Diagnostics). Participants provided 
informed consent for additional blood sampling and stor-
age, as described previously.20–22 The analysis population was 
defined in the substudy using the same inclusion and exclu-
sion criteria as for the trial population.
Cardiac Troponin Testing
As previously described, cardiac troponin testing was per-
formed at presentation and repeated 6 or 12 hours after the 
onset of symptoms at the discretion of the attending clini-
cian in accordance with national and international guidelines 
in use during enrollment.19,23,24 In all patients during both 
phases of the trial, cardiac troponin was measured using 
the ARCHITECTSTAT high-sensitive troponin I assay (Abbott 
Laboratories, Abbott Park, IL). This assay has a limit of detec-
tion of between 1.2 ng/L and 1.9 ng/L,25 and for consistency 
with prior studies we defined this as any concentration <2 
ng/L.26 For the purpose of this analysis, all patients with an 
undetectable troponin concentration were assigned a value 
of 1.0 ng/L. The inter-assay coefficient of variation is less than 
10% at 4.7 ng/L and the sex-specific 99th centile diagnostic 
thresholds are 16 ng/L for women and 34 ng/L for men.27 
High-sensitivity cardiac troponin I concentrations were only 
disclosed to clinicians during the implementation phase of the 
trial, but given risk stratification thresholds were not used to 
guide clinical decisions we pooled data from both phases of 
the trial for the purpose of this analysis.
In the substudy, samples were also analyzed using the 
Siemens Atellica high-sensitivity cardiac troponin I assay and 
Roche Elycsys high-sensitivity cardiac troponin T assays.5,22 
For these assays the limit of detection is 1.6 ng/L and 5 ng/L 
respectively, and the limit of blank for the cardiac troponin T 
assay is 3 ng/L. For all 3 assays, we evaluated performance of 
the risk stratification threshold of 5 ng/L, the lower thresh-
old of <2 ng/L for cardiac troponin I, and <3 ng/L for cardiac 
troponin T, as these thresholds are equivalent to the limit of 
detection and limit of blank, respectively.
Adjudication of the Diagnosis of 
Myocardial Infarction
Clinical information was collected from a standardized elec-
tronic patient record (TrakCare; InterSystems Corporation, 
Cambridge, MA) linked to local and national datasets. 
Electrocardiographic data including algorithmic interpretation 
was available by electronic capture in a subgroup of patients 
(MUSE, GE Healthcare). All unique interpretation codes gen-
erated by this system (n=4291) were reviewed by a consensus 
panel who selected codes consistent with possible ischemia 
(n=180). Example electrocardiograms featuring these codes 
were then reviewed independently by at least 2 physicians 
to determine reliability for clinically significant myocardial 
ischemia. The final list of 119 codes (see Appendix in the 
online-only Data Supplement) were then applied to the study 
population with electronic electrocardiograms to determine 
whether myocardial ischemia was present for each patient.
Two physicians from our adjudication panel indepen-
dently reviewed all clinical information to classify patients 
with any high-sensitivity cardiac troponin measurement 
>99th centile on serial testing during the index presenta-
tion in accordance with the third Universal Definition of 
Myocardial Infarction.28 Myocardial infarction following 
discharge and all death outcomes were also independently 
adjudicated by 2 physicians blinded to study phase and any 
disagreements were resolved by a third physician.
Study Outcomes
The primary safety outcome was type 1 or 4b myocardial 
infarction during the index presentation, or subsequent type 
1 or 4b myocardial infarction or cardiac death within 30 
days of the index presentation. The secondary safety out-
come was subsequent type 1 or 4b myocardial infarction 
or cardiac death at 12 months. Type 2 myocardial infarction 
was not included in the composite outcome, as by defini-
tion these patients present with alternative, often noncar-
diac conditions that determine whether they require hospital 
admission or discharge.
The number and proportion of patients with high-sensi-
tivity cardiac troponin concentrations less than 2 ng/L or 5 
ng/L at presentation were measured to evaluate effectiveness 
of these risk stratification thresholds. Secondary outcomes of 
cardiac catheterization, coronary intervention and new medi-
cal therapy were collected from local and national databases 
as previously described.19
Statistical Analysis
Baseline characteristics are summarized as percentages for 
categorical variables, mean (standard deviation) or median 
(interquartile range) as appropriate. The negative predictive 
value was determined using 2×2 tables to calculate the true 
and false negative rates for the primary outcome, comparing 
patients with cardiac troponin concentrations at presentation 
less than 2 ng/L and less than the risk stratification threshold 
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of 5 ng/L. As we expected the negative predictive value to 
approach 100%, we estimated the proportion by sampling 
from a binomial likelihood distribution with a Jeffreys prior, 
as such approaches have good coverage for proportions that 
approach 0 or 1 (ß distribution shape parameters both 0.5).29 
Analysis by stratification was used to compare performance 
in different subgroups. For age, the negative predictive value 
was calculated for each integer age value between 20 and 
90 years, and plotted with a line of best fit and 95% CI. The 
negative predictive value was also determined separately in 
those with and without prior history of ischemic heart dis-
ease, diabetes mellitus, stroke, heart failure and renal impair-
ment (estimated glomerular filtration rate <60 mL/min/1.73 
m2 determined by Modified Diet in Renal Disease equation) or 
myocardial ischemia on the electrocardiogram at presentation.
For the secondary outcome, the rates of myocardial infarc-
tion or cardiac death were compared in patients with cardiac 
troponin concentration at presentation less than 2 ng/L, less 
than 5 ng/L, and 5 ng/L to the sex-specific 99th centile. In a 
post-hoc analysis, we also compared the rates of myocardial 
infarction or cardiac death in patients with cardiac troponin 
concentrations between these risk stratification thresholds. 
Logistic regression modelling for the primary and secondary 
outcomes was performed using patients with cardiac tropo-
nin concentrations between 5 ng/L and the sex-specific 99th 
centile as a reference group. Odds ratios were adjusted for 
differences in age and sex. All analyses were performed using 
R (version 3.5.1).
RESULTS
The trial enrolled 48 282 consecutive patients (61±17 
years, 47% women) across 10 hospitals in Scotland. A 
total of 32 837 patients (68%) remained in the analysis 
population (58±1 years, 47% women) after excluding 
those with cardiac troponin concentrations >99th cen-
tile at presentation (n=7795), and those presenting ≤2 
hours of symptom onset (n=6469) or with ST-segment 
elevation myocardial infarction (n=925), and where the 
high-sensitivity cardiac troponin concentrations at pre-
sentation were missing (n=256; Figure I in the online-
only Data Supplement).
Proportion and Characteristics of 
Patients Identified by Risk Stratification 
Thresholds
In our analysis population, 23 260 (71%) had a cardiac 
troponin concentration below 5 ng/L, and 9577 (29%) 
were between 5 ng/L and the 99th centile. There were 
12 716 (39%) patients with cardiac troponin concentra-
tions below 2 ng/L at presentation. Patients with car-
diac troponin concentrations below these risk stratifica-
tion thresholds were younger, more likely to be female, 
and had fewer cardiovascular risk factors than those 
with troponin concentrations between 5 ng/L and the 
99th centile (Table 1). Similarly, the use of antiplatelet 
agents and secondary prevention were half as frequent 
in patients with cardiac troponin concentrations below 
5 ng/L compared with those above this threshold. In 
those below 2 ng/L, even lower rates of cardiovascular 
risk factors were observed amongst younger, predomi-
nantly female patients when compared with those with 
troponin concentrations 2–4 ng/L (Table I in the online-
only Data Supplement).
Diagnostic Performance of Risk 
Stratification Thresholds
In the analysis population, 1.6% (517 of 32 837) of pa-
tients experienced a primary outcome event of index 
myocardial infarction, or subsequent myocardial infarc-
tion or cardiac death within 30 days of presentation. This 
composite measure included 475 patients with an index 
myocardial infarction, and 78 and 49 patients with a 
subsequent myocardial infarction or cardiac death within 
30 days, respectively. The majority of composite events 
occurred in those with cardiac troponin concentrations 
between 5 ng/L and the 99th centile where the event 
rate was 4.8% (462 of 9577) at 30 days. There were 55 
events in 23 260 patients (0.2%) with cardiac troponin 
concentrations less than 5 ng/L, and 15 events in the 
subgroup of 12 716 patients (0.1%) less than 2 ng/L. Of 
these composite events, cardiac death within 30 days oc-
curred in 45 of 9577 patients with troponin concentra-
tions between 5 ng/L and the 99th centile (0.5%), 4 of 
23 260 patients less than 5 ng/L (0.02%) and 1 patient 
from 12 716 below 2 ng/L (0.01%, Table 2).
The negative predictive value for the primary outcome 
at 30 days in patients with cardiac troponin concentra-
tions less than the risk stratification threshold of 5 ng/L 
at presentation was 99.8% (95% CI, 99.7%–99.8%). 
The negative predictive value in the subgroup of patients 
with cardiac troponin concentrations <2 ng/L was 99.9% 
(95% CI, 99.8%–99.9%). Although the prevalence of 
the primary outcome varied between sites (range, 0.8%–
2.1%), the negative predictive value remained consistent 
across all sites (Table II in the online-only Data Supple-
ment). In patients presenting within 2 hours of symptom 
onset (n=6469), the negative predictive value was lower 
at both thresholds (99.0% [95% CI, 98.7%–99.3%] for 
those <5 ng/L and 99.6% [95% CI, 99.3%–99.8%] for 
patients <2 ng/L, Table III in the online-only Data Supple-
ment). Confusion matrices and other diagnostic metrics 
for the trial and analysis populations are shown in Tables 
IV and V in the online-only Data Supplement.
Diagnostic Performance of Risk 
Stratification Thresholds in Subgroups
The proportion of patients with cardiac troponin con-
centration below the 5 ng/L and 2 ng/L thresholds 
varied markedly by age, but the negative predictive 
value of these approaches to risk stratification were 
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identical across all age groups (Figure  1). The lower 
bounds of the 95% CI was >99.5% for both thresholds 
even in the oldest patients. In patients >65 years old 
(n=11 837), the proportion identified as low risk with 
a high-sensitivity troponin concentration below the 2 
ng/L risk stratification threshold was diminished at only 
11% (1303 of 11 837), compared with 46% (5463 of 
11 837) with cardiac troponin concentrations <5 ng/L.
Central estimates of negative predictive value were 
below 99.5% for both risk stratification thresholds in 
patients with a prior history of ischemic heart  disease, 
diabetes mellitus, stroke, heart failure and renal im-
pairment, although the upper bound of the 95% CIs 
crossed the prespecified safety margin of 99.5% (Fig-
ure  2). In those with available electronic electrocar-
diograms and evidence of myocardial ischemia, the 
negative predictive value was 99.6% (95% CI, 99.3%–
99.9%) in those with cardiac troponin concentrations 
less than 5 ng/L and 99.7% (95% CI, 99.2%–100.0%) 
in those below 2 ng/L.
The proportion of patients with cardiac troponin 
concentrations below both thresholds differed widely 
Table 1. Baseline Characteristics of Participants, by Presentation hs-cTnI
Characteristics All
Presentation hs-cTnI
<2 ng/L
2 ng/L –
99th centile <5 ng/L
5 ng/L –
99th centile
Demographics
  No. of patients 32 837 12 716 20 121 23 260 9577
  Age, y 58.4 (17.1) 47.8 (13.9) 65.1 (15.4) 53.6 (15.7) 70.1 (14.5)
  Male sex 17 478 (53) 5620 (44) 11 858 (59) 11 519 (50) 5959 (62)
Presenting complaint
  Chest pain 24 085 (73) 9793 (77) 14 292 (71) 17 830 (77) 6255 (65)
  Dyspnea 1001 (3) 169 (1) 832 (4) 398 (2) 603 (6)
  Palpitation 825 (3) 269 (2) 556 (3) 540 (2) 285 (3)
  Syncope 1162 (4) 216 (2) 946 (5) 574 (3) 588 (6)
  Other 1197 (4) 306 (2) 891 (4) 722 (3) 475 (5)
Past medical history
  Ischemic heart disease 7467 (23) 1309 (10) 6158 (31) 3863 (17) 3604 (38)
  Myocardial infarction 2537 (8) 432 (3) 2105 (11) 1287 (6) 1250 (13)
  Stroke or transient ischemic attack 1700 (5) 231 (2) 1469 (7) 735 (3) 965 (10)
  Percutaneous coronary intervention 2416 (7) 461 (4) 1955 (10) 1351 (6) 1065 (11)
  Coronary artery bypass grafting 477 (2) 58 (1) 419 (2) 207 (1) 270 (3)
  Diabetes mellitus 1867 (6) 253 (2) 1614 (8) 782 (3) 1085 (11)
  Heart failure 1956 (6) 130 (1) 1826 (9) 535 (2) 1421 (15)
Medications
  Aspirin 8277 (25) 1654 (13) 6623 (33) 4619 (20) 3658 (38)
  Clopidogrel 2555 (8) 437 (3) 2118 (11) 1307 (6) 1248 (13)
  Ticagrelor 225 (1) 43 (0.3) 182 (1) 129 (1) 96 (1)
  Oral anticoagulant 1951 (6) 219 (2) 1732 (9) 753 (3) 1198 (13)
  ACE inhibitor or ARB 9799 (30) 1969 (16) 7830 (39) 5470 (24) 4329 (45)
  ß-blocker 8398 (26) 1943 (15) 6455 (32) 4863 (21) 3535 (37)
  Statin 12 264 (37) 2594 (20) 9670 (48) 7002 (30) 5262 (55)
  Loop diuretics 3420 (10) 356 (3) 3064 (15) 1176 (5) 2244 (23)
Laboratory results
  Presentation hs-cTnI 2.4 [1.0, 5.7] 1.0 [1.0, 1.1] 4.5 [2.9, 8.7] 1.6 [1.0, 2.8] 9.0 [6.3, 14.0]
  Peak hs-cTnI 2.7 [1.0, 6.0] 1.0 [1.0, 1.3] 5.0 [3.0, 9.7] 1.8 [1.0, 3.0] 10.0 [7.0, 15.5]
  Serial hs-cTnI test 13 554 (41) 4552 (36) 9002 (45) 8954 (39) 4600 (48)
  GFR, mL/min/1.73 m2 88 (24) 96 (19) 82 (25) 92 (21) 76 (27)
Data are number of patients (%), mean (SD), or median [IQR].
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; GFR, glomerular filtration rate; and hs-cTnI, high-sensitivity cardiac 
troponin I.
D
ow
nloaded from
 http://ahajournals.org by on December 13, 2019
Bularga et al High-Sensitivity Troponin for Risk Stratification
November 5, 2019 Circulation. 2019;140:1557–1568. DOI: 10.1161/CIRCULATIONAHA.119.0428661562
OR
IG
IN
AL
 R
ES
EA
RC
H 
AR
TI
CL
E
in these subgroups, but in every subgroup with prior 
cardiovascular disease, at least twice as many patients 
were identified as low risk using a risk stratification 
threshold of 5 ng/L compared with 2 ng/L (Figure 3). In-
vasive cardiac procedures and changes to preventative 
cardiac medications were rarely undertaken or initiated 
following emergency department assessment (Table VI 
in the online-only Data Supplement). Cardiac catheter-
ization occurred in fewer than 1 in 100 patients below 
either threshold and new antiplatelet therapy was com-
menced in fewer than 1 in 25.
Secondary Safety Outcomes at 12 
months
Subsequent myocardial infarction or cardiac death fol-
lowing discharge from hospital occurred in 2.0% (667 
of 32 837) of patients at 12 months. Event rates were 
similar between patients with cardiac troponin concen-
trations at presentation below 2 ng/L and 5 ng/L (35 of 
12 716 [0.3%] vs 161 of 23 260 [0.7%], respectively), 
and were lower than those with cardiac troponin con-
centrations of 5 ng/L to the 99th centile at presenta-
tion (506 of 9577 [5.3%]; Table 2 and Figure 4). Lower 
cardiac troponin concentrations were associated with 
fewer subsequent events at 12 months; patients with 
concentrations <2 ng/L had a lower event rate than 
those with concentrations between these thresholds 
(126 of 10 544 [1.2%], Figure II in the online-only Data 
Supplement). When accounting for substantial differ-
ences in age and sex between these groups, the risk 
of subsequent myocardial infarction or cardiac death 
at 12 months was 80% lower in those below 2 ng/L 
(adjusted odds ratio, 0.20 [95% CI, 0.14–0.29]), and 
77% lower in those less than 5 ng/L (adjusted odds ra-
tio, 0.23 [95% CI, 0.19–0.28]), compared with patients 
with troponin concentrations between 5 ng/L and the 
99th centile. At both 30 days and 1 year, adjusted risk 
estimates of myocardial infarction and cardiac death 
were similar for those with cardiac troponin concentra-
tions <2 ng/L and <5 ng/L, and for those patients with 
concentrations between these thresholds (adjusted 
odds ratio, 0.30 [95% CI, 0.24–0.36], Table VII in the 
online-only Data Supplement).
Diagnostic Performance of Risk 
Stratification Thresholds for Different 
High-Sensitivity Assays
In our substudy, 1185 patients presenting more than 2 
hours from symptom onset were evaluated using the 
Siemens Atellica cardiac troponin I assay, and 1042 
patients evaluated using the Roche Elecsys troponin T 
assay (Table VIII in the online-only Data Supplement). 
Using the Siemens assay, 55% and 15% of patients 
had a cardiac troponin I concentration <5 ng/L and <2 
ng/L at presentation with a negative predictive value of 
99.3% (95% CI, 98.5%–99.8%) and 99.2% (95% CI, 
97.4%–99.9%), respectively. For the cardiac troponin T 
assay, 46% and 24% of patients were <5 ng/L and <3 
ng/L at presentation, with a negative predictive value of 
99.1% (95% CI, 98.0%–99.7%) and 99.4% (95% CI, 
98.2%–99.9%) respectively (Table IX in the online-only 
Data Supplement).
DISCUSSION
In this prespecified secondary analysis from the High-
STEACS trial, we have evaluated the use of risk strati-
fication thresholds for high-sensitivity cardiac troponin 
I in 32 837 consecutive patients with suspected acute 
coronary syndrome. We report several important find-
ings for clinicians managing patients with this common 
presentation. First, in patients with at least 2 hours of 
symptoms prior to testing, a cardiac troponin concen-
Table 2. Logistic Regression Modelling for Safety Outcomes at 30 Days and 12 Months, by Presentation hs-cTnI
5 ng/L - 99th centile (n=9577) <2 ng/L (n=12 716) <5 ng/L (n=23 260)
No. of 
Events (%)
Odds Ratio 
(Reference)
No. of 
Events
Odds Ratio 
(95% CI)
Adjusted Odds 
Ratio
No. of 
Events
Odds Ratio 
(95% CI)
Adjusted Odds 
Ratio
30 Days
  Myocardial infarction 59 (0.6) 1.00 3 (0.0) 0.06 (0.02–0.17) 0.10 (0.02–0.28) 19 (0.1) 0.13 (0.08–0.22) 0.17 (0.10–0.31)
  Cardiac death 45 (0.5) 1.00 1 (0.0) 0.03 (0.00–0.15) 0.16 (0.01–0.76) 4 (0.0) 0.04 (0.01–0.09) 0.10 (0.03–0.26)
  Myocardial infarction 
or cardiac death
99 (1.0) 1.00 4 (0.0) 0.05 (0.02–0.13) 0.12 (0.03–0.29) 23 (0.1) 0.09 (0.06–0.15) 0.16 (0.09–0.25)
12 Months
  Myocardial infarction 282 (2.9) 1.00 25 (0.2) 0.11 (0.07–0.16) 0.20 (0.13–0.31) 105 (0.5) 0.15 (0.12–0.19) 0.23 (0.18–0.30)
  Cardiac death 253 (2.6) 1.00 11 (0.1) 0.06 (0.03–0.10) 0.19 (0.10–0.34) 60 (0.3) 0.10 (0.07–0.13) 0.23 (0.16–0.31)
  Myocardial infarction 
or cardiac death
506 (5.3) 1.00 35 (0.3) 0.09 (0.06–0.12) 0.20 (0.14–0.29) 161 (0.7) 0.12 (0.10–0.15) 0.23 (0.19–0.28)
Excluding index events. Odds ratios are derived from logistic regression models comparing the group with presentation hs-cTnI <2 ng/L or <5 ng/L against the 
reference group 5 ng/L – 99th centile (95% CIs). Adjusted odd ratios include age and sex in the logistic regression model. 
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tration below 5 ng/L identifies a group at very low risk 
of immediate or future cardiac events, with a negative 
predictive value greater than 99.5%. Second, this per-
formance is maintained regardless of age, sex, and the 
presence of myocardial ischemia on the electrocardio-
gram. Third, using a risk stratification threshold of 5 
ng/L identifies twice as many patients as low risk at pre-
sentation when compared with the limit of detection. 
Fourth, the negative predictive value of applying a risk 
stratification threshold of 5 ng/L is consistent across 
high-sensitivity cardiac troponin I and T assays. Fifth, 
patients with cardiac troponin concentrations above 
the risk stratification threshold of 5 ng/L, but below 
the diagnostic threshold, represent a high-risk group 
with a 7-fold greater risk of subsequent myocardial 
infarction or cardiac death over 12 months compared 
with those below either risk stratification threshold. 
Taken together, we suggest the use of separate risk 
stratification and diagnostic thresholds for cardiac tro-
ponin, will substantially improve our ability to iden-
tify patients at risk compared with the binary approach 
used in practice today.
High-STEACS is the largest clinical trial to evaluate 
consecutive patients with suspected acute coronary 
syndrome reported to date.19 This analysis of 32 837 
patients is larger than the combined number of patients 
from 30 observational cohort studies, who were includ-
ed in 2 recent major retrospective meta-analyses of risk 
stratification using high-sensitivity cardiac troponin I 
and T.8,9 The negative predictive value of the risk strati-
fication threshold of 5 ng/L for myocardial infarction or 
cardiac death at 30 days was found to be 99.5% (95% 
CI, 99.3%–99.6%) across 19 of these cohorts using car-
diac troponin I,8 which is similar to the 99.8% (95% CI, 
99.7%–99.8%) observed here, and was 99.3% (95% 
CI, 97.3%–99.8%) in 11 cohorts using cardiac troponin 
T.9 Taken together these findings suggest that a single 
risk stratification threshold could be safely applied for 
both high-sensitivity cardiac troponin I and T assays.
The American Heart Association/American College of 
Cardiology and European Society of Cardiology guide-
lines for the management of acute coronary syndromes 
recommend the diagnostic threshold for myocardial in-
farction at the 99th centile as an appropriate limit for 
exclusion in patients except in early presenters.3,30 Alter-
native approaches have been suggested, such as those 
described in the recent COMPASS-MI study, which uses 
a range of thresholds in combination with serial testing 
and change between two cardiac troponin measures to 
estimate the negative and positive predictive value for 
Figure 1. Performance of cardiac troponin I risk stratification thresholds by age. 
Negative predictive value for the primary outcome of myocardial infarction or cardiac death at 30 days across a range of ages with 95% confidence intervals 
(shaded) for patients with cardiac troponin concentrations below 2 ng/L (gray) and 5 ng/L (red) at presentation. The negative predictive value was calculated for 
each integer age value between 20 and 90 years, and plotted with a line of best fit and 95% CI. The bar chart shows the proportion of patients in each 5-year age 
band with cardiac troponin concentrations below each threshold.
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individual patients.5 As demonstrated in our prior work, 
the gain in effectiveness from increasing the threshold 
above 5 ng/L is small, and the negative predictive value 
for our safety outcome is lower than 99.5% at higher 
concentrations.19 Similarly, the 0/1 hour pathway rec-
ommended by the European Society of Cardiology uses 
multiple thresholds, but not the 99th centile to rule in 
and rule out myocardial infarction, at presentation or 
at 1 hour.30–32
These varied approaches acknowledge that patients 
without myocardial injury at presentation are at risk of 
cardiovascular events; in the present study more than 1 
in 20 patients with cardiac troponin measures between 
the risk stratification and diagnostic thresholds expe-
rienced a subsequent myocardial infarction or cardiac 
death within 12 months of presentation. Troponin is a 
continuous marker of cardiovascular risk and low con-
centrations can be used to estimate long-term cardio-
vascular risk.33–35 This can be informative for clinical de-
cision making, but results need to be interpreted in the 
context of the individual patient, and these thresholds 
have not been optimized for this purpose. However, 
what is clear is that those with intermediate troponin 
concentrations are at higher risk of future events, and 
the use of the 99th centile alone does not appear to be 
an appropriate threshold to risk stratify patients with 
suspected acute coronary syndrome.
There are a number of strengths to our study. The 
trial design avoided selection bias through the inclusion 
of consecutive patients ensuring our analysis popula-
tion included both low- and high-risk individuals, an 
equal proportion of men and women, patients who 
presented outside routine hours, and those who were 
unlikely to survive. Enrollment was across 10 hospitals 
in Scotland including both secondary and tertiary care 
centers. Despite differences in the prevalence of the 
primary outcome between sites, the proportion of pa-
tients identified as low risk and the safety of risk stratifi-
cation with cardiac troponin was consistent across sites. 
Within our substudy, we have further explored the gen-
eralizability of our findings, demonstrating equivalent 
diagnostic performance of the same risk stratification 
threshold for other high-sensitivity cardiac troponin I 
and T assays. By using robust and established regional 
and national registries we ensured follow-up was com-
plete in all patients who remained resident in Scotland 
through linkage of electronic health-care records.36,37 
Finally, all primary or secondary outcome events were 
Figure 2. Safety of cardiac troponin I risk stratification thresholds by subgroups. 
Forest plot showing the number of patients in each subgroup, true negatives (TN) and false negatives (FN) with the negative predictive value (NPV) for the primary 
outcome, stratified by patients with cardiac troponin concentrations below 2 ng/L (black) and below 5 ng/L (red). *ECG ischemia data available in 7167/32 837 
(22%) of patients.
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adjudicated in accordance with the Universal Definition 
of Myocardial Infarction.
There are approximately 20 million presentations 
with suspected acute coronary syndrome to the emer-
gency departments in the United States and Europe 
every year.38 The adoption of a safe and effective ap-
proach to rule out of myocardial infarction would have 
a considerable impact on healthcare provision. Using 
an optimized risk stratification threshold of 5 ng/L com-
pared with the limit of detection (<2 ng/L) identifies 
twice as many low-risk patients. This is particularly rel-
evant in older patients with established cardiovascular 
disease, where the clinical assessment of pretest prob-
ability is more challenging. The optimized risk stratifi-
Figure 3. Proportion of patients identified as low risk at the <2 ng/L and <5 ng/L risk stratification thresholds by subgroups.  
Proportion of patients in each subgroup with cardiac troponin concentrations below 2 ng/L (gray) or 5 ng/L (red) at presentation.
Figure 4. Cumulative incidence of myocardial infarction or cardiac death at 12 months.  
Plots stratified by cardiac troponin concentration at presentation: (A) below 2 ng/L (gray) and between 2 ng/L and 99th centile (blue); (B) below 5 ng/L (red) and 
between 5 ng/L and 99th centile (blue).
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cation threshold maintains an excellent safety profile 
across all age groups and identifies 4 times as many 
patients >65 years old as low risk. It is well recognized 
that cardiac troponin concentrations increase with 
age39 where they reflect the presence and control of 
traditional cardiovascular risk factors, such as hyperten-
sion40 and hypercholesterolemia,25 the burden of cor-
onary artery disease,26,27 vulnerable plaque,41 and left 
ventricular hypertrophy or myocardial fibrosis.42,43 This 
property of cardiac troponin as a dynamic barometer 
of heart health44 provides the pathophysiological basis 
to explain its powerful role in the risk stratification of 
patients with suspected acute coronary syndrome.39
Although the safety profile of both the 5 ng/L and 
2 ng/L thresholds appear excellent, prospective trials in 
which patients are assessed and clinical decisions are 
guided using this approach are needed to ensure that 
the very low event rates observed here are not a con-
sequence of hospital admission for further investiga-
tion and treatment. In our present analysis, we confirm 
our previous findings in patients who present within 2 
hours of symptoms onset, and suggest that serial test-
ing is required in early presenters to maintain the very 
high negative predictive value of this approach in all 
patient groups (Table III in the online-only Data Supple-
ment).6 In those presenting more than 2 hours from 
symptom onset, we further explored the performance 
of risk stratification thresholds across subgroups. De-
spite our large sample size, it is possible we were un-
derpowered to evaluate safety in smaller subgroups, 
such as those with a prior history of ischemic heart dis-
ease, diabetes mellitus, stroke, heart failure and renal 
impairment. In these subgroups, the central estimate, 
but not the upper bound of the CI for the negative pre-
dictive value, was below 99.5% for both risk stratifica-
tion thresholds. There was evidence of heterogeneity 
between those with and without prior ischemic heart 
disease. However, even in those with established risk 
factors or cardiovascular conditions, all estimates of 
negative predictive value encompassed our prespecified 
safety margin of 99.5%. The safety and effectiveness 
of introducing risk-stratification thresholds into clinical 
practice is currently being addressed in the HiSTORIC 
trial (High-Sensitivity Cardiac Troponin on Presentation 
to Rule Out Myocardial Infarction; https://www.clinical-
trials.gov. Unique identifier: NCT03005158), and in the 
LoDED study (Limit of Detection of Troponin and ECG 
Discharge; ISRCTN 86184521).45
There are some study limitations relevant to this 
analysis. We were unable to report use of noninva-
sive diagnostic testing in our study population, and 
electrocardiograms were only available for a propor-
tion of patients. However, our analysis shows that the 
negative predictive value of the optimized risk stratifi-
cation threshold and 2 ng/L was similar in the presence 
or absence of myocardial ischemia. In the absence of 
 ST-segment elevation, other abnormalities on the elec-
trocardiogram appear to be less important in patients 
who have very low cardiac troponin concentrations. 
This analysis evaluates the risk stratification threshold of 
a single troponin assay, but we have provided evidence 
in our substudy of the consistency of this approach for 
other high-sensitivity cardiac troponin I and T assays. 
Recent reports also support the validity of this approach 
across differing high-sensitivity cardiac troponin I and T 
assays.9,12,22,46 The assay’s precision and analytical varia-
tion16,17 at the risk stratification threshold is likely to in-
fluence the clinical utility of using very low cardiac tro-
ponin concentrations, and we have not evaluated assay 
performance or the implications of misclassification 
here. Although the trial was conducted across 10 differ-
ent hospitals in Scotland, all are part of a single health-
care system, and additional studies would be helpful 
in countries where less selective cardiovascular testing 
is performed.47 However, we have previously observed 
similar safety and effectiveness in a meta-analysis of 19 
cohorts across 9 countries.8
In conclusion, the use of a risk stratification thresh-
old for high-sensitivity cardiac troponin I in the evalu-
ation of patients with suspected acute coronary syn-
drome presenting at least 2 hours from symptom onset 
identifies the majority of patients at low risk of immedi-
ate and future cardiovascular events. The use of an op-
timized risk stratification threshold of 5 ng/L compared 
with 2 ng/L, classifies twice as many patients as low 
risk. Although the proportion identified as low risk is 
reduced in older patients, the safety of this approach 
is maintained across patients irrespective of age or sex. 
The adoption of risk stratification thresholds in clinical 
practice has potential to improve both the effectiveness 
and safety of the evaluation of patients with suspected 
acute coronary syndrome with major benefits for pa-
tients and healthcare providers.
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